Results 31 to 40 of about 4,697 (156)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Journal of Hematology & Oncology, 2022
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension.
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison   +17 more
doaj   +1 more source

Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib [PDF]

This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Bajwa, N, Sharman, JP, Miranda, P, Ghia, P, Rule, S, Shaw, B, Seymour, JF   +6 more
core   +2 more sources

Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia

Фармакоэкономика
Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib + venetoclax” regimen for treatmentnaive adults with chronic lymphocytic leukemia (CLL), unmutated IGHV, and absence of del(17p) or mutations in TP53 in the ...
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Lutova, E. A. Popova   +4 more
doaj   +1 more source

Acalabrutinib Approved for MCL

, 2018
The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.

core   +1 more source

Acalabrutinib: First Global Approval

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Anthony Markham is a contracted employee of Adis/Springer, is responsible for the article contentand declares no ...
Anthony Markham (4891627), Sohita Dhillon (4873375)   +1 more
core   +1 more source

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma [PDF]

The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely ...
Patti Caterina, Belada David, Morawska Marta, Chu Michael P, Cheah Chan Y, Salek David, Dreyling Martin, Kryachok Iryna, Forsyth Cecily, Zhang Jingyang, Rule Simon, Fogliatto Laura, Sancho Juan-Manuel, Borbényi Zita, Ramadan Safaa, Kollaborációs szervezet: ECHO investigators, Kahl Brad S, Song Yuqin, Paludo Jonas, Jurczak Wojciech, Li Yufu, Wang Michael, Lesley Robin   +22 more
core   +1 more source

Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling

Pharmaceuticals, 2021
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median duration of survival of approximately 14 months after diagnosis. High resistance to chemotherapy remains a major problem.
Yu-Kai Su, Oluwaseun Adebayo Bamodu, I-Chang Su, Narpati Wesa Pikatan, Iat-Hang Fong, Wei-Hwa Lee, Chi-Tai Yeh, Hsiao-Yean Chiu, Chien-Min Lin   +8 more
doaj   +1 more source

Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States

, 2023
Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib. A semi-Markov model with three health states (progression-free, progressed disease, and death)
Priyanka Gaitonde (15203357), Kellie Ryan (8595495), Bengt Liljas (15203354), Victoria Genovez (15203348), Talha Munir (3520109), Victor Genestier (15203351)   +5 more
core   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]

Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon, Byrd, John C, Lai, Tzung-Huei, Munugalavadla, Veerendra, Robak, Tadeusz, Jurczak, Wojciech, Woyach, Jennifer A, Rule, Simon, Lai, Richard, Illés, Árpád, Mohamed, Nehad, Jones, Daniel, Kater, Arnon P, Seymour, John F, Ghia, Paolo, Long, Susan, de Bruin, Gerjan, De Jesus, Gary   +17 more
core   +2 more sources